AGILeBiotics BV was launched in March 2017 as a spin-off company from Groningen University. AGILe Biotics is an early-stage pharmaceutical company, which is covering all expertise and knowledge required for the development of novel aminoglycoside antibiotics thanks to regional, national and international collaborations with industry and academic institution.

In the second round of investment in July 2018, Pharma Connect Capital joint the company as shareholder. AgileBiotics aims to start clinical studies in 2020.